EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

被引：21

作者：

Balar, Arjun Vasant ^{[1
]}

McGregor, Bradley Alexander ^{[2
]}

Rosenberg, Jonathan E. ^{[3
]}

van der Heijden, Michiel Simon ^{[4
]}

Park, Se Hoon ^{[5
]}

Lee, Jae-Lyun ^{[6
,7
]}

Harrison, Michael Roger ^{[8
]}

Heath, Elisabeth, I ^{[9
]}

Stein, Mark N. ^{[10
]}

Loriot, Yohann ^{[11
]}

Necchi, Andrea ^{[12
]}

Steinberg, Joyce Leta ^{[13
]}

Liang Shang-Ying ^{[14
]}

Kim, Eric ^{[15
]}

Trowbridge, Janet ^{[16
]}

Campbell, Mary S. ^{[14
]}

Petrylak, Daniel Peter ^{[17
]}

Yu, Evan Y. ^{[18
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Samsung Med Ctr, Dept Med, Div Hematol Oncol, Seoul, South Korea

[6] Asan Med Ctr, Seoul, South Korea

[7] Univ Ulsan, Coll Med, Seoul, South Korea

[8] Duke Univ, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA

[9] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[10] Columbia Univ, Med Ctr, New York, NY USA

[11] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[12] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[13] Astellas Pharma Inc, Northbrook, IL USA

[14] Seattle Genet Inc, Bothell, WA USA

[15] Seattle Genet, Bothell, WA USA

[16] JTrowbridge, Edmonds, WA USA

[17] Yale Sch Med, New Haven, CT USA

[18] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.394

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

394

引用

页数：3